New hope for lymphoma patients Who've run out of options
NCT ID NCT06563505
Summary
This study is testing whether combining two medications—mosunetuzumab and zanubrutinib—can help control a type of blood cancer called marginal zone lymphoma that has come back or hasn't responded to previous treatments. The trial will enroll 36 adults to see how well the combination works and how safe it is. Researchers will measure if the treatment shrinks or eliminates the cancer and how long patients benefit from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.